Research programme: antiviral therapeutics - Jenthera Therapeutics
Alternative Names: Antiviral therapeutics - Jenthera TherapeuticsLatest Information Update: 23 Nov 2023
Price :
$50 *
At a glance
- Originator Jenthera Therapeutics
- Class Antivirals; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Viral infections
Most Recent Events
- 24 Aug 2023 Research programme: antiviral therapeutics is available for licensing as of 24 Aug 2023. https://www.jenthera.com/programs
- 24 Aug 2023 Early research in Viral infections in Canada (IV) before August 2023 (Jenthera Therapeutics pipeline, August 2023)